Table 1.
Main demographic and clinical features of the two groups.
| Variable |
Danlou Tablet group (n = 109) |
Placebo group (n = 110) |
χ 2 (Z) | p value |
|---|---|---|---|---|
| Age, yr | 62.89 ± 9.23 | 63.89 ± 10.03 | 0.04 | 0.44 |
| Men, number (%) | 72 (66.1) | 74 (67.3) | 0.04 | 0.85 |
| Body weight, kg | 66.91 ± 10.14 | 66.65 ± 9.54 | −0.6 | 0.55 |
| Height, cm | 166.41 ± 6.85 | 166.00 ± 8.17 | −0.23 | 0.82 |
| Family history of coronary disease, number (%) | 18 (16.5) | 10 (9.1) | 2.71 | 0.10 |
| Concomitant diseases, number (%) | ||||
| Previous coronary heart disease | 41 (37.6) | 47 (42.7) | 0.60 | 0.44 |
| Previous coronary intervention | 9 (8.3) | 17 (15.5) | 2.71 | 0.10 |
| Systemic hypertension | 51 (46.8) | 63 (57.3) | 2.41 | 0.12 |
| Diabetes mellitus | 21 (19.3) | 19 (17.3) | 0.15 | 0.70 |
| Dyslipidemia | 38 (34.9) | 38 (34.5) | 0.002 | 0.96 |
| Heart failure | 1 (0.9) | 4 (3.6) | 0.37^∗ | |
| Arrhythmia | 4 (3.7) | 10 (9.1) | 2.69 | 0.10 |
| Stroke | 7 (6.4) | 8 (7.3) | 0.06 | 0.80 |
| Current smoker, number (%) | 47 (43.1) | 44 (40.0) | 0.22 | 0.64 |
| Cardiac Marker Elevation, number (%) | 30 (27.5%) | 33 (30.0%) | 0.16 | 0.69 |
| Clinical pattern, number (%) | ||||
| Unstable angina | 88 (80.7) | 87 (79.1) | 0.09 | 0.76 |
| NSTEMI | 21 (19.3) | 23 (20.9) | ||
| Cardiac function, number (%) | ||||
| Level I | 41 (37.6) | 41 (37.3) | 0.03 | 0.99 |
| Level II | 53 (48.6) | 53 (48.2) | ||
| Level III | 15 (13.8) | 16 (14.5) |
Values are given as number of patients (%) or mean ± SD. NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; and ARB, angiotensin II receptor blocker. ∗ p value is from Fisher's exact test.